What is he best known for?
The fields of study he is best known for:
- Internal medicine
- Psychiatry
- Dopamine
Ross J. Baldessarini mainly investigates Psychiatry, Bipolar disorder, Internal medicine, Depression and Pediatrics.
In his research, Ross J. Baldessarini undertakes multidisciplinary study on Psychiatry and Suicide prevention.
His work carried out in the field of Bipolar disorder brings together such families of science as Lithium and Mood.
Ross J. Baldessarini has included themes like Quetiapine, Endocrinology, Olanzapine and Antipsychotic in his Internal medicine study.
His Pediatrics course of study focuses on Survival analysis and Age of onset.
His studies in Mania integrate themes in fields like Anxiety and Comorbidity.
His most cited work include:
- International Consensus Study of Antipsychotic Dosing (812 citations)
- One hundred years of schizophrenia: a meta-analysis of the outcome literature. (627 citations)
- Clozapine. A novel antipsychotic agent. (584 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Psychiatry, Internal medicine, Bipolar disorder, Depression and Endocrinology.
As part of his studies on Psychiatry, Ross J. Baldessarini frequently links adjacent subjects like Clinical psychology.
Ross J. Baldessarini interconnects Placebo, Olanzapine and Antipsychotic in the investigation of issues within Internal medicine.
His biological study spans a wide range of topics, including Major depressive disorder, Mood disorders, Anxiety and Pediatrics.
His research in the fields of Antidepressant overlaps with other disciplines such as Suicide prevention and Suicidal ideation.
His work deals with themes such as Agonist and Serotonin, which intersect with Endocrinology.
He most often published in these fields:
- Psychiatry (54.35%)
- Internal medicine (32.37%)
- Bipolar disorder (35.06%)
What were the highlights of his more recent work (between 2012-2021)?
- Psychiatry (54.35%)
- Bipolar disorder (35.06%)
- Depression (22.38%)
In recent papers he was focusing on the following fields of study:
Ross J. Baldessarini spends much of his time researching Psychiatry, Bipolar disorder, Depression, Clinical psychology and Major depressive disorder.
Ross J. Baldessarini carries out multidisciplinary research, doing studies in Psychiatry and Suicide prevention.
His Bipolar disorder study incorporates themes from Substance abuse, Internal medicine, Lithium and Pediatrics.
His Internal medicine research includes elements of Quetiapine, Aripiprazole and Endocrinology.
His Depression research includes themes of Long term morbidity and MEDLINE.
His Clinical psychology research focuses on Schizophrenia and how it connects with Psychosis.
Between 2012 and 2021, his most popular works were:
- The International Society for bipolar Disorders (ISBD) task force report on antidepressant use in bipolar disorders (413 citations)
- Chemotherapy in psychiatry (253 citations)
- Longitudinal neuroimaging and neuropsychological changes in bipolar disorder patients: review of the evidence. (154 citations)
In his most recent research, the most cited papers focused on:
- Internal medicine
- Psychiatry
- Major depressive disorder
Ross J. Baldessarini mainly focuses on Bipolar disorder, Psychiatry, Depression, Mania and Internal medicine.
His studies deal with areas such as Lamotrigine, Quetiapine, Anxiety, Antidepressant and Pediatrics as well as Bipolar disorder.
Ross J. Baldessarini regularly links together related areas like Clinical psychology in his Psychiatry studies.
He interconnects Long term morbidity and MEDLINE in the investigation of issues within Depression.
His study looks at the relationship between Mania and fields such as Substance abuse, as well as how they intersect with chemical problems.
The concepts of his Internal medicine study are interwoven with issues in Psychosocial and Relapse prevention.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
